CMG Pharmaceutical Co. Ltd (058820) - Total Liabilities
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has total liabilities worth ₩104.41 Billion KRW (≈ $70.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 058820 long-term investment intensity to see how much of total assets are deployed in long-term investments.
CMG Pharmaceutical Co. Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how CMG Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 058820 total assets.
CMG Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QTC Energy Public Company Limited
BK:QTC
|
Thailand | ฿1.25 Billion |
|
Elon AB (publ)
ST:ELON
|
Sweden | Skr1.53 Billion |
|
Asia Pacific Wire & Cable Corp Ltd
NASDAQ:APWC
|
USA | $168.90 Million |
|
Techbond Group Bhd
KLSE:5289
|
Malaysia | RM35.55 Million |
|
Helbor Empreendimentos S.A
SA:HBOR3
|
Brazil | R$3.91 Billion |
|
BenQ Medical Technology
TWO:4116
|
Taiwan | NT$3.24 Billion |
|
StoneBridge Ventures Inc.
KQ:330730
|
Korea | ₩7.20 Billion |
|
Thai Nippon Rubber Industry Public Co. Ltd
BK:TNR
|
Thailand | ฿1.27 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down CMG Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of CMG Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CMG Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CMG Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual total liabilities of CMG Pharmaceutical Co. Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩104.41 Billion ≈ $70.75 Million |
-8.33% |
| 2024-12-31 | ₩113.89 Billion ≈ $77.18 Million |
+119.60% |
| 2023-12-31 | ₩51.87 Billion ≈ $35.15 Million |
+83.22% |
| 2022-12-31 | ₩28.31 Billion ≈ $19.18 Million |
+95.60% |
| 2021-12-31 | ₩14.47 Billion ≈ $9.81 Million |
+1.74% |
| 2020-12-31 | ₩14.22 Billion ≈ $9.64 Million |
+17.71% |
| 2019-12-31 | ₩12.08 Billion ≈ $8.19 Million |
+16.22% |
| 2018-12-31 | ₩10.40 Billion ≈ $7.05 Million |
-10.55% |
| 2017-12-31 | ₩11.62 Billion ≈ $7.88 Million |
+17.75% |
| 2016-12-31 | ₩9.87 Billion ≈ $6.69 Million |
+1.50% |
| 2015-12-31 | ₩9.73 Billion ≈ $6.59 Million |
+7.28% |
| 2014-12-31 | ₩9.07 Billion ≈ $6.14 Million |
+31.10% |
| 2013-12-31 | ₩6.92 Billion ≈ $4.69 Million |
-72.90% |
| 2012-12-31 | ₩25.52 Billion ≈ $17.29 Million |
+175.24% |
| 2011-12-31 | ₩9.27 Billion ≈ $6.28 Million |
-- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more